Frontiers in Pharmacology | Pharmacology of Anti-Cancer Drugs

Original Research

Published on 29 May 2025

A multimodal approach for establishing ACTL6A and ERCC1 as chemoresistance genes in locally advanced head and neck cancer

in Pharmacology of Anti-Cancer Drugs

Raushan Kumar Chaudhary
Prakash Patil
Vijith Vittal Shetty
Uday Venkat Mateti
Praveenkumar Shetty

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1541987

504 views

Original Research

Published on 29 May 2025

Polypharmacy, drug–drug interactions and adverse drug reactions in older Chinese cancer patients: evidence from CHARLS

in Pharmacology of Anti-Cancer Drugs

Zijun Yan
Ke-qin Fan
Ting Yu
Ning Su
Yan Zou
Liangjing Xia

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1579023

414 views

Original Research

Accepted on 28 May 2025

Tricin selectively combats KRAS-mutant non-small cell lung cancer by inhibiting the PDGF-BB-induced SRC/MAPK/AP-1/PD-L1 signaling pathway and potentiating the antitumor effect of an anti-PD-1 antibody

in Pharmacology of Anti-Cancer Drugs

Jia-Xin Li
Shi-Yu Tan
Li-Qi Li
Yu-Hong Zheng
Lin Zhao
Hui-Rong Zhu
Hailang He
Yan-Yu Zhang
Run-Ze Li
Tian-Yu Bao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1594213

216 views

Review

Accepted on 28 May 2025

Multiple myeloma inhibitory effects of natural compounds: enhancement through nanoparticle carriers

in Pharmacology of Anti-Cancer Drugs

Xinyu Wang
Erica Wong
Anna Staskiewicz
Joshua Pruner
Jean Lee
Michael Tucker
Barkley Smith
Lanerica Rogers
Ganiat Asuni

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1589090

162 views

Original Research

Accepted on 27 May 2025

Targeted Degradation of EGFR 19Del by Protac Suppresses Tumor Growth in Non-Small Cell Lung Cancer

in Pharmacology of Anti-Cancer Drugs

Lianhua Piao
Ying Gao
Yangyang Su
Qihui Li
Xiaofeng Yuan
Wangqiu He
Wanzhou Zhao
Janne Kulpakko
Pei-Chieng Cha
Shan Chang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1604661

169 views

Original Research

Published on 27 May 2025

Efficacy and safety of Tislelizumab combined with Axitinib as first-line treatment for intermediate- and high-risk metastatic clear-cell renal cell carcinoma

in Pharmacology of Anti-Cancer Drugs

Jie Cui
Pengyong Xu
Changying Guo
Yong Guan
Kejia Zhu
Sentai Ding

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1618898

470 views

Review

Published on 27 May 2025

Unravelling the link between circadian clock genes and brain tumors: From pathological disruptions to potential therapeutic interventions

in Pharmacology of Anti-Cancer Drugs

Amirah Albaqami

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1617713

588 views

Original Research

Published on 27 May 2025

Anticancer effects of zinc ion-mediated DNA demethylation in oesophageal squamous cell carcinoma

in Pharmacology of Anti-Cancer Drugs

Bin Zhou
Changchun Wang
Yueyu Huang
Xuping Yang
Ting Ye
Lize Shen
Qiaoli Lv
Weimin Mao
An Zhao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1559675

483 views

Original Research

Published on 27 May 2025

Isoliensinine exerts antitumor effects in lung adenocarcinoma by inhibiting APEX1-driven ROS production

in Pharmacology of Anti-Cancer Drugs

Cheng Chen
Chenying Shu
Dan Shen
Zhaowei Yan
Zeyi Liu
Jian-An Huang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1555802

442 views

Original Research

Accepted on 26 May 2025

Identification of an Ara-C Resistance-Related Gene Risk Score and the Role of S100A4 in AML via NR6A1-Dependent Activation and p53 Regulation

in Pharmacology of Anti-Cancer Drugs

Li Wang
Huang Aoshuang
Bingqing Cheng
Xiuying Hu
Jishi Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1574759

190 views

Original Research

Accepted on 26 May 2025

Autophagy inhibition induced by EM-2 augments apoptosis via ROSmediated ATM-Chk2-p53-p21 and MAPK pathway in lung and breast carcinoma

in Pharmacology of Anti-Cancer Drugs

Jinxia Cheng
Qi Chen
Ning Cao
Chuyu He
Yanjun Xu
Xiaoying Zhang
Qiang Li
Hong Hong
Jianwei Jiang
Yuechun Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1580217

116 views

Review

Published on 23 May 2025

Current paradigm and futuristic vision on new-onset diabetes and pancreatic cancer research

in Pharmacology of Anti-Cancer Drugs

Russell Moreland
Abigail Arredondo
Anupam Dhasmana
Swati Dhasmana
Shabia Shabir
Asfia Siddiqua
Bonny Banerjee
Murali M. Yallapu
Stephen W. Behrman
Subhash C. Chauhan

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1543112

849 views

Original Research

Published on 23 May 2025

Immune-related gene risk model establishment and role of key gene FUCA1 in malignant pleural mesothelioma

in Pharmacology of Anti-Cancer Drugs

Lin Shi
Dongqi Yuan
Fuyi Zhu
Yuchao He
Ran Zuo
Liwei Chen
Yi Luo
Yu Wang
Dingzhi Huang
Peng Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1577232

627 views

Original Research

Published on 22 May 2025

Multi-omics and single-cell approaches reveal molecular subtypes and key cell interactions in hepatocellular carcinoma

in Pharmacology of Anti-Cancer Drugs

Xueqing Zou
Yongmei Wang
Mingyuan Luan
Yizheng Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1605162

933 views

Case Report

Published on 21 May 2025

Perforation of the descending colon induced by alectinib in a patient with non-small cell lung cancer: a Case Report

in Pharmacology of Anti-Cancer Drugs

Yun Li
Ping Yu
Ran Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1545614

545 views

Review

Published on 20 May 2025

Selinexor in acute myeloid leukemia: therapeutic applications and current challenges

in Pharmacology of Anti-Cancer Drugs

Ziyu Qie
Li Ma
Jie Tan
Xiaochun Peng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1602911

662 views